PRESS RELEASE
20th November 2019
Mogrify wins Seed Stage Finance Raise of the Year
at 2019 European Lifestars Awards
Celebrating success across life sciences
Cambridge, UK, 20th November 2019: Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies, is pleased to announce that it has been recognized as the winner of the Seed Stage Finance Raise of the Year award at the 2019 Lifestars Awards™.
In February 2019, Mogrify announced it had raised $3.7 million USD seed funding, which the Company is using to produce cell types with unrivaled safety, efficacy and scalability profiles using its proprietary direct cellular conversion technology. The seed funding round was led by Ahren Innovation Capital, with investments from 24Haymarket and Dr. Darrin M. Disley, OBE.
Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry over the last 12 months across Europe.
The international awards bring together hundreds of global life science leaders, investors and deal makers and key stakeholders from the wider eco-system to recognize the achievements of the industry. 19 awards were contested during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK on the 19th November. The Awards supported Teenage Cancer Trust as the official Charity beneficiary.
European Lifestars Awards forms a signature, evening networking function during the Investival Showcase and Jefferies Annual Healthcare Conference week in London, Europe’s largest healthcare investment banking conference.
“Lifestars presents a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s testament to Mogrify’s efforts that this year’s judging faculty have recognized them in this manner.” Neil Darkes, Co-CEO, LSX Ltd. and Lifestars
“We are honored to have received the award for Seed Stage Finance Raise of the Year at this year’s Lifestars Awards. This is a tribute to the hard work and dedication of Mogrify’s passionate team, our partners and our investors. The Company has grown rapidly since February, and we will continue to engage with high-caliber investors and other innovators in the cell therapy space.” Dr. Darrin M. Disley, OBE, CEO, Mogrify
Notes to Editors
The award was presented to Dr. Aida Moreno-Moral, Principal Bioinformatician (second from left) and Dr. Rodrigo Santos, Director of Cell Technologies (right), at Mogrify.
For high-resolution and alternate images please contact Zyme Communications.
For further information please contact:
Mogrify
Darrin M. Disley, PhD, OBE
Tel: + 44 (0)1223 734154
Email: [email protected]
Lifestars
Neil Darkes
Tel: +44 (0)203 637 5908
Email: [email protected]
Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811 996 942
E-mail: [email protected]
To opt-out from receiving press releases from Zyme Communications please e-mail [email protected]. To view our privacy policy, please click here.
About Mogrify www.mogrify.co.uk
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.
Mogrify is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.
Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify
About LifestarsTM
The LifestarsTM Awards are organized by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit www.lsxleaders.com/lifestars-awards